Earnings · Pharma · Q2 FY27 results declared
The Alkem Laboratories Q2 results date was Thursday, 12 November 2026, and the numbers are out: revenue up 13.8% to Rs 4,552 crore, profit before tax up 11.6% and net profit down 11.7% to Rs 675.3 crore as the tax charge tripled. This page keeps the date, the base and the guidance marks, and links to the full Alkem Laboratories Q2 results FY27 analysis.
Quick answer
The Alkem Laboratories Q2 results date was Thursday, 12 November 2026. Revenue was Rs 4,551.99 crore, up 13.8%, and net profit was Rs 675.34 crore, down 11.7% from Rs 765.06 crore, because tax rose to about 33% of profit before tax, per Upstox, Multibagg and Free Press Journal.
Latest update (Thursday, 12 November 2026, 4:00 PM IST): Alkem reported Q2 FY27 consolidated results on Thursday, 12 November 2026, with the first reports at about 2:00 PM IST. I found no dividend announcement, no analyst consensus and no official closing price, and I have not opened the exchange filing. The earlier preview marks are kept below so the result can be checked against them.
Key takeaways
- Date: the board met on Thursday, 12 November 2026, as CompoundingAI had reported; the first reports appeared at about 2:00 PM IST, before the 4:30 pm call.
- Result: revenue Rs 4,551.99 crore (+13.8%) and net profit Rs 675.34 crore (-11.7%), against the Rs 4,001 crore and Rs 765.1 crore base on this page.
- Tax: about 33.2% of profit before tax against about 13.0% a year earlier, after about 32.6% in Q1 (my calculation); profit before tax rose 11.6%.
- Margin: EBITDA margin was 22.5% against 23.0% and above the 20% to 21% guidance mark; EBITDA grew 11.3%.
- Conflict: profit appears as Rs 675.34 crore and as Rs 667.1 crore, and one headline says EBITDA grew 22.5% when the arithmetic gives 11.3%.
- Still open: no dividend, no official close and no consensus found.
In plain words: Alkem Laboratories is an Indian pharmaceutical company that sells branded medicines in India and generic medicines in the US and other countries. Its profit depends on sales growth, the margin on those sales and the tax it pays.
Data note: Figures are as of 12 November 2026, 4:00 PM IST. Q2 FY27 figures come from Upstox, Free Press Journal and Multibagg; earlier figures from Business Standard, Investywise, Kotak Neo and CompoundingAI. I could not open the company filings. Derived numbers are my calculation. Guidance quoted from a source is that source’s, not mine.
In this post
- What did Alkem report?
- When was the results date and time?
- What was the base to beat?
- What did Q1 FY27 show?
- How did the result compare with the guidance marks?
- What drives the quarter?
- How did the results compare with the scenarios?
- Decoder: what the filing answered
- How to read the filing
- What most people miss
- FAQs
- Sources
What did Alkem report on the Alkem Laboratories Q2 results date?
On the Alkem Laboratories Q2 results date, 12 November 2026, Alkem reported revenue of Rs 4,551.99 crore (+13.8%), EBITDA of Rs 1,025.2 crore (+11.3%), profit before tax of Rs 999.7 crore (+11.6%) and net profit of Rs 675.34 crore (-11.7%), per Upstox, Multibagg and Free Press Journal.
| Line (Rs crore, consolidated) | Q2 FY27 reported | Q2 FY26 base | Q1 FY27 | Outcome |
|---|---|---|---|---|
| Revenue from operations | 4,551.99 | 4,001 | 3,740 | Above both: +13.8% and +21.7% |
| EBITDA | 1,025.2 | 920.8 | 766.6 | Above the base, +11.3% |
| EBITDA margin | 22.5% | 23.0% | 20.5% | Below the base; above Q1 |
| Profit before tax | 999.7 | 895.8 | Not found | +11.6% on the base |
| Tax expense | 331.9 | 116.2 | 251 | About 33.2% of PBT against 13.0% |
| Net profit | 675.34 | 765.1 | 520 | Below the base; +29.9% on Q1 |
Cite this table: Alkem Q2 FY27 against the preview marks, as of 12 November 2026, 4:00 PM IST, PositionalCalls; Q2 FY27 per Upstox, Multibagg and Free Press Journal.
The full line-by-line analysis, with the tax arithmetic, the segments, the cash position and the price, is in Alkem Laboratories Q2 results FY27. Here I keep the date, the base and the guidance marks that the preview raised. The preview said Q1 profit fell because of tax and named the tax rate as the line to read first. Q2 repeated the pattern: profit before tax rose 11.6% while tax rose about 186% (my calculation). The figures are as reported by news sources and I have not opened the exchange filing.
When was the Alkem Laboratories Q2 results date and time?
The board met on Thursday, 12 November 2026 to approve results for the quarter and half-year ended 30 September 2026, as CompoundingAI reported from the 4 November intimation. The first reports appeared at about 2:00 PM IST, before the 4:30 pm earnings call.
The first report I found is Multibagg at 2:00 PM IST, followed by Upstox (updated 3:01 PM) and Free Press Journal (3:07 PM). I did not find the exact filing time and could not open the exchange intimation. The call from 4:30 pm to 5:30 pm hosted by Motilal Oswal is separate from the filing. Companies must report within 45 days of the quarter-end, which made Saturday, 14 November the limit; Alkem reported on day 43 (my calculation). Upstox also reports that the board appointed Gopal Kothari as Chief Financial Officer, effective 2 December 2026.
| Item | What was reported | Source and date | Status |
|---|---|---|---|
| Board meeting | 12 November 2026 | CompoundingAI, citing the 4 Nov intimation | Held |
| Agenda | Q2 and H1 FY27 results | CompoundingAI | Done |
| Results | Revenue Rs 4,551.99 crore; profit Rs 675.34 crore | Upstox; Multibagg; FPJ, 12 Nov | Reported |
| Results time | First reports about 2:00 PM IST | Multibagg | Filing time not found |
| Dividend | No announcement found | Reports read | Check the filing |
| Analyst consensus | None found | Searches | Not available |
Cite this table: Alkem Laboratories Q2 results date status, as of 12 November 2026, 4:00 PM IST, PositionalCalls.
See the Q2 results hub for the other reporters.
What was the profit and revenue base Alkem had to beat in Q2 FY27?
The Q2 FY26 base was consolidated revenue of Rs 4,001 crore, up 17.2%, EBITDA of Rs 920.8 crore at a 23.0% margin and net profit of Rs 765.1 crore, up 11%. India sales were Rs 2,766 crore and international sales Rs 1,189 crore. Q2 FY27 revenue cleared it by 13.8%; net profit fell short by 11.7%.
| Q2 FY26 (quarter to 30 Sep 2025), consolidated | Figure | Change | Source |
|---|---|---|---|
| Revenue from operations | Rs 4,001 crore (Rs 40,010 million) | +17.2% (from Rs 3,414.7 crore) | Business Standard; Investywise |
| EBITDA | Rs 920.8 crore | +22%; margin 23.0% | Business Standard; Investywise |
| Net profit | Rs 765.1 crore (Rs 7,651 million) | +11% (from Rs 688.6 crore); margin 19.1% | Business Standard; Investywise |
| India sales | Rs 2,766 crore | +14% (Business Standard); +12.4% (Investywise) | Business Standard; Investywise |
| International sales | Rs 1,189 crore | +29.5% | Business Standard; Investywise |
| US sales | Rs 764.9 crore | +28% | Business Standard; Investywise |
| Research and development | Rs 130.2 crore | 3.3% of revenue | Investywise |
Cite this table: Alkem Laboratories Q2 FY26 base, consolidated, as reported; margins checked by PositionalCalls.
The numbers tie: Rs 920.8 crore on Rs 4,001 crore is 23.0% and Rs 765.1 crore is 19.1% of revenue (my calculation). Two figures do not tie across sources. India sales growth is 14% in Business Standard and 12.4% in Investywise, and Business Standard’s statement that international is 31.7% of revenue does not match Rs 1,189 crore on Rs 4,001 crore, which is 29.7% (my calculation). I show both and use the computed share.
Standalone, consolidated and profit attributable
This page uses consolidated figures. Two profit figures circulate for Q2 FY27: Rs 675.34 crore against Rs 765.06 crore (Upstox, Multibagg; earnings per share Rs 56.48) and Rs 667.1 crore against Rs 779.1 crore (Free Press Journal, which matches the Rs 779 crore Outlook Business gave for Q2 FY26). The gaps run in opposite directions, which suggests a different profit line, probably the split between owners and minority holders, but I could not confirm that. Match the line to the filing before any comparison.
What did Alkem report in Q1 FY27, the nearest mark?
In Q1 FY27 Alkem reported consolidated revenue of Rs 3,740 crore, up 10.9%, and net profit of Rs 520 crore, down 21.7% from Rs 664 crore. EBITDA was Rs 766.6 crore at 20.5%. Tax expense rose to Rs 251 crore from Rs 103 crore.
| Q1 FY27 (quarter to 30 June 2026), consolidated | Q1 FY27 | Q1 FY26 | Change |
|---|---|---|---|
| Revenue from operations | Rs 3,740 crore | Rs 3,371 crore | +10.9% |
| EBITDA | Rs 766.6 crore | Rs 660 crore | +16.2% (Kotak Neo) |
| EBITDA margin | 20.5% | 19.6% | +0.9 point |
| Net profit | Rs 520 crore | Rs 664 crore | -21.7% |
| Tax expense | Rs 251 crore | Rs 103 crore | Up Rs 148 crore |
| India sales | Rs 2,497.8 crore | Not found | +10.3% |
| International sales | Rs 1,222.3 crore | Not found | +16% |
Cite this table: Alkem Laboratories Q1 FY27 as reported by Kotak Neo; ties checked by PositionalCalls.
These tie: Rs 766.6 crore on Rs 3,740 crore is 20.5% and Rs 660 crore on Rs 3,371 crore is 19.6%, and India plus international sales of Rs 3,720.1 crore (my calculation) leave about Rs 19.9 crore of other operating revenue. The profit fall is a tax story: adding tax to profit gives a pre-tax figure and a tax rate of about 32.6% in Q1 FY27 against 13.4% in Q1 FY26 (my calculation, ignoring minority interest). Q2 FY27 repeated the tax step-up: tax was about 33.2% of profit before tax (my calculation). CompoundingAI reports Q1 EBITDA up 3.7% and the margin down about 140 basis points, which conflicts with Kotak Neo’s +16.2% and +0.9 point; the Kotak figures tie to the revenue, so I use them.
What has Alkem’s management guided for FY27?
CompoundingAI reports management guidance of an FY27 EBITDA margin of 20% to 21%, a gross margin of 66.5% to 67%, a tax rate of 30% to 32% and India growth 100 to 150 basis points above the market. These are third-party summaries.
| Guidance item | Reported FY27 guidance | Compare with |
|---|---|---|
| EBITDA margin | 20% to 21% | 23.0% in Q2 FY26; 20.5% in Q1 FY27 |
| Gross margin | 66.5% to 67% | 67.9% in Q1 FY27 |
| Consolidated tax rate | 30% to 32% (from 35% to 38%) | About 32.6% in Q1 FY27 (my calculation) |
| India growth | 100 to 150 bps above the market | 13.2% against 12.2% in Q1 |
| US growth | Mid to high single digit, helped by the rupee | +6.5% in Q1 |
| Enzene CDMO | Breakeven targeted for FY28 | Needs about $25 to $30 million annualised revenue |
Cite this table: Alkem Laboratories FY27 guidance as summarised by CompoundingAI from the Q1 call; not verified against the transcript.
PositionalCalls WhatsApp channel
The results, then the tax and margin check
- The revenue, margin and profit lines as soon as they appear
- Tax and guidance explained
- Links to the updated page
| Mark (CompoundingAI, unverified) | Mark range | Q2 FY27 actual | Reading, my calculation |
|---|---|---|---|
| FY27 EBITDA margin | 20% to 21% | 22.5% | Above the range |
| FY27 gross margin | 66.5% to 67% | 67.2% (Multibagg) | Slightly above |
| FY27 tax rate | 30% to 32% | About 33.2% | Above the range |
| India growth against the market | 100 to 150 bps above | Chronic +640 bps; India total not tied | Cannot test |
| US growth | Mid to high single digit | +2.4% | Below |
Cite this table: Alkem marks as recorded from CompoundingAI (single source); Q2 comparison by PositionalCalls. Not verified against management statements.
Q2 FY27 came in above the margin range and the tax range, and below the US mark (my calculation). CompoundingAI also reports that Occlutech sales of about Rs 400 crore for 8.5 months would be “a bit off” guidance, that the Daman facility exit from an FDA classification is expected in 6 to 12 months from August 2026, and that a US denosumab entry is planned for end-2026 subject to Amgen litigation.
What drives Alkem’s Q2 numbers: India, the US, margin and tax?
Four lines drive the quarter: India sales growth against the market, US and international sales, the EBITDA margin and the tax rate. In Q1 FY27 profit fell because tax rose, while revenue and EBITDA grew. Q2 FY27 repeated that: India sales Rs 3,027.5 crore (+9.5%), US Rs 783 crore (+2.4%), margin 22.5% and tax about 33.2%.
| Driver | Q2 FY26 | Q1 FY27 | What to read in the filing |
|---|---|---|---|
| India sales | Rs 2,766 crore | Rs 2,497.8 crore, +10.3% | Growth against the market |
| International sales | Rs 1,189 crore, +29.5% | Rs 1,222.3 crore, +16% | Whether growth recovers |
| EBITDA margin | 23.0% | 20.5% | Level against 20% to 21% guidance |
| Tax expense | Not found | Rs 251 crore (about 32.6%) | Rate against 30% to 32% guidance |
| Net profit | Rs 765.1 crore | Rs 520 crore | Whether profit recovers |
Cite this table: Alkem Laboratories driver checklist, PositionalCalls; figures from the sources above.
How did the actual Alkem results compare with the scenario tables?
Reported revenue of Rs 4,552 crore sits just below the +15% row, and EBITDA of Rs 1,025 crore sits between the 20.5% and 23.0% margin columns at the +12% to +15% rows (it was a 22.5% margin). Net profit of Rs 675 crore sits between the Rs 600 crore and Rs 700 crore rows. The tables were arithmetic illustrations, not forecasts.
| Revenue growth on Q2 FY26 | Revenue, Rs crore | EBITDA at 20.5% margin | EBITDA at 23.0% margin |
|---|---|---|---|
| +8% | 4,321 | 885.8 | 993.8 |
| +10.9% (Q1 pace) | 4,437 | 909.6 | 1,020.5 |
| +12% | 4,481 | 918.6 | 1,030.7 |
| +15% | 4,601 | 943.2 | 1,058.3 |
Cite this table: Alkem Laboratories Q2 FY27 arithmetic, my calculation. Base: Q2 FY26 revenue Rs 4,001 crore; Q2 FY26 EBITDA was Rs 920.8 crore. Not forecasts.
| Net profit level, Rs crore | Change vs Q2 FY26 base (765.1) | Change vs Q1 FY27 (520) |
|---|---|---|
| 600 | -21.6% | +15.4% |
| 700 | -8.5% | +34.6% |
| 765.1 | 0.0% | +47.1% |
| 850 | +11.1% | +63.5% |
Cite this table: Alkem Laboratories Q2 FY27 profit arithmetic, my calculation. Levels are illustrations, not forecasts.
What did the filing answer? Alkem results-day decoder
On results day the reading order was: revenue against Rs 4,001 crore and Rs 3,740 crore, EBITDA margin against 23.0% and 20.5%, tax rate, net profit against Rs 765.1 crore and Rs 520 crore, then India and US sales.
| Order | Line to read | Mark to compare | Why it comes first |
|---|---|---|---|
| 1 | Revenue from operations | Rs 4,001 crore; Rs 3,740 crore | Top-line trend |
| 2 | EBITDA and margin | Rs 920.8 crore at 23.0%; 20.5% | Cost and mix |
| 3 | Tax expense and rate | Rs 251 crore; about 32.6% | Drove the Q1 profit fall |
| 4 | Net profit | Rs 765.1 crore; Rs 520 crore | The headline |
| 5 | India and international sales | Rs 2,497.8 crore; Rs 1,222.3 crore (Q1) | Growth mix |
| 6 | Dividend | None mentioned | Check the filing |
Cite this table: Alkem Laboratories results-day reading order, PositionalCalls.
| Decoder question | Answer from the reports (12 Nov 2026) | Status |
|---|---|---|
| Revenue above Rs 4,001 crore and Rs 3,740 crore? | Rs 4,551.99 crore, +13.8% and +21.7% | Yes |
| EBITDA margin near 23.0% or 20.5%? | 22.5% | Between the two |
| Tax rate near 32.6% or lower? | About 33.2% | Slightly higher |
| Profit above Rs 765.1 crore? | Rs 675.34 crore (or Rs 667.1 crore), -11.7% | No |
| India and US sales growth? | India +9.5%; US +2.4% | Reported |
| Dividend? | No announcement found | Check the filing |
Cite this table: PositionalCalls, Alkem decoder answers, as of 12 November 2026; figures as reported, filing not opened.
Compare like with like: use consolidated lines against consolidated marks, and check which profit line each report uses.
How do I read the Alkem filing and avoid fake alerts?
To check the results, open the NSE or BSE announcement for Alkem Laboratories, not a link in a message, and read the results table first. Treat any tip that asks for an OTP, payment or login as fake.
- Open the exchange announcement page for Alkem Laboratories Limited.
- Read the unaudited consolidated results for the quarter ended 30 September 2026.
- Note revenue, EBITDA, tax and profit.
- Compare with Rs 4,001 crore, Rs 920.8 crore and Rs 765.1 crore.
- Check any dividend or other announcement.
- Check the investor presentation for India and US sales.
PositionalCalls is not SEBI-registered, gives no buy or sell calls and never asks for payment. Nothing here is investment advice.
What do most people miss about the Alkem Laboratories Q2 results date?
Around the Alkem Laboratories Q2 results date, most readers see profit down 12% and miss that profit before tax rose 11.6%, that tax was about 33% against 13%, that a Rs 35 crore exceptional gain helped and that two profit figures circulate.
A last point on sources. Most figures here come from news summaries of the company’s filings, and rounding and definitions differ between them: Upstox and Multibagg quote profit of Rs 675.34 crore while Free Press Journal quotes Rs 667.1 crore, and one headline states EBITDA growth of 22.5% when the arithmetic gives 11.3%. Before using any number from the Alkem Laboratories Q2 results date in a decision, open the exchange filing, check whether it is standalone or consolidated, look at the split of profit between owners and minority holders and note the date of the report. I list each source with its time below so the comparison can be repeated. Where a figure on this page is my own calculation, such as the tax rate or the profit before tax without the exceptional gain, the text says so, and the inputs are in the tables so the arithmetic can be checked line by line.
Bottom line
The Alkem Laboratories Q2 results date was 12 November 2026. Alkem reported revenue of Rs 4,551.99 crore (+13.8%), EBITDA of Rs 1,025.2 crore, profit before tax of Rs 999.7 crore and net profit of Rs 675.34 crore (-11.7%), with tax at about 33% of profit before tax. There is no target or call here. See the full Alkem Laboratories Q2 results FY27 analysis and our stock market coverage.
PositionalCalls WhatsApp channel
Never miss a results update
- Results dates and dividend dates
- Numbers explained without tips or targets
- Updated posts as they go live
Alkem Laboratories Q2 results date: frequently asked questions
When was the Alkem Laboratories Q2 results date?
The Alkem Laboratories Q2 results date was Thursday, 12 November 2026, when the board met to approve results for the quarter and half-year ended 30 September 2026, per CompoundingAI. The first reports appeared at about 2:00 PM IST, before the 4:30 pm call. I did not find the filing time.
What was Alkem net profit in Q2 FY27?
Net profit was Rs 675.34 crore against Rs 765.06 crore a year earlier, down 11.7%, on revenue of Rs 4,551.99 crore, up 13.8%, per Upstox and Multibagg. Free Press Journal shows Rs 667.1 crore against Rs 779.1 crore, a likely different basis. These answer the Alkem Laboratories Q2 results date comparison; the filing is the reference.
Why did Alkem profit fall when revenue rose?
Tax expense rose to Rs 331.9 crore from Rs 116.2 crore, about 33.2% of profit before tax against about 13.0%, my calculation from Free Press Journal figures. Profit before tax itself rose 11.6%. A Rs 35 crore exceptional gain helped. The reports do not explain the higher tax rate.
What was Alkem EBITDA margin in Q2 FY27?
EBITDA was Rs 1,025.2 crore against Rs 920.8 crore, up 11.3%, and the margin was 22.5% against 23.0%, per Multibagg. That is above the 20% to 21% FY27 guidance mark recorded here from CompoundingAI. One Upstox headline says EBITDA grew 22.5%, which is the margin, not the growth.
What was the Alkem profit base for Q2 FY27?
The Q2 FY26 base was consolidated profit of Rs 765.1 crore on revenue of Rs 4,001 crore and EBITDA of Rs 920.8 crore at a 23.0% margin, per Business Standard and Investywise. Outlook Business showed Rs 779 crore. The Q2 FY27 growth rates tie to that base within rounding.
How did the result compare with the FY27 guidance marks?
CompoundingAI summarised guidance of an EBITDA margin of 20% to 21%, a tax rate of 30% to 32% and mid to high single-digit US growth. Q2 had a margin of 22.5%, tax near 33.2% and US growth of 2.4%, my calculation. The marks are unverified, so check the transcript.
Did Alkem declare a dividend with Q2 results?
I did not find a dividend announcement with the Q2 result, and the sources I read for the meeting did not mention one. Upstox reports that the board appointed Gopal Kothari as Chief Financial Officer, effective 2 December 2026. Check NSE and BSE announcements for any dividend and record date.
How did Alkem India and US sales do in Q2 FY27?
India sales were Rs 3,027.5 crore, up 9.5% from Rs 2,766 crore, and US sales were Rs 783 crore, up 2.4% from Rs 764.9 crore, per Upstox and my earlier base. International sales were Rs 1,454 crore, up 22.3%, helped by non-US growth including Occlutech.
Upstox reported that the shares fell as much as 5.05% on 12 November 2026 to an NSE low of Rs 5,173, with a market capitalisation of Rs 62,891.19 crore. The time of the low is not given and I did not find the official close for the Alkem Laboratories Q2 results date.
Is this financial advice about Alkem?
No. This page is not investment advice, a target or a recommendation, and PositionalCalls is not SEBI-registered. It reports company figures and sources with dates, and labels my calculations. Read the exchange filing and consult a registered adviser before any decision.
Sources
- Upstox: Alkem Laboratories Q2 profit falls 12%, 12 November 2026, updated 3:01 PM IST.
- Free Press Journal: Alkem Laboratories Q2 profit falls 14%, 12 November 2026, 3:07 PM IST.
- Multibagg: Alkem Q2 revenue rises 13.8%, profit drops 11.7%, 12 November 2026, 2:00 PM IST.
- PositionalCalls: Alkem Laboratories Q2 results FY27 analysis
- NSE India: corporate announcements: where the results appear.
- BSE India: corporate announcements: the results filing.
- CompoundingAI: Alkem Q2 FY27 preview: date, call and guidance.
- Kotak Neo: Alkem Q1 FY27 results, 14 August 2026.
- Business Standard: Alkem Q2 profit rises 11%, 13 November 2025.
- Investywise: Alkem Q2 FY26 results, November 2025.
Disclosure: PositionalCalls.com is not a SEBI-registered research analyst or investment adviser. Investments in securities markets are subject to market risks. Read all related documents carefully before investing. Returns are never guaranteed. PositionalCalls is an independent research and education site founded by Shubham Chaudhary. Nothing here is a recommendation, target or investment advice. How I researched this: for the Alkem Laboratories Q2 results date I read CompoundingAI, Kotak Neo, Business Standard and Investywise, noted where sources differ, and marked every derived number as my calculation. I did not open any company filing or exchange document. Figures are as of 12 November 2026, 4:00 PM IST.
Shubham Chaudhary is the founder of PositionalCalls, an independent Indian stock market research website. He writes company fundamentals, quarterly results analysis, IPO analysis and sector research for NSE and BSE listed companies, with a focus on banking stocks, insurance and long-term value investing. Every article is built from primary sources such as RBI, SEBI, NSE and BSE filings and company annual reports, and states its risks plainly in simple language for retail investors.
Coverage areas Our research standards- Numbers checked against NSE, BSE and SEBI filings
- Risks and limits stated in every article
- No paid promotions or broker tie-ups
- Articles updated when new filings arrive